Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2017 / Article

Review Article | Open Access

Volume 2017 |Article ID 4505194 | https://doi.org/10.1155/2017/4505194

Yaohan Wang, Li Feng, Bingkui Piao, Peitong Zhang, "Review on Research about Traditional Chinese Medicine in Cancer Stem Cell", Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 4505194, 10 pages, 2017. https://doi.org/10.1155/2017/4505194

Review on Research about Traditional Chinese Medicine in Cancer Stem Cell

Academic Editor: Shuang-En Chuang
Received05 Feb 2017
Revised23 May 2017
Accepted15 Jun 2017
Published04 Oct 2017


Cancer stem cells (CSCs) are small subpopulations of neoplastic cells within a tumor, which have self-renewal and differentiation abilities and could generate new tumors with few cells. Researches have showed that CSCs are considered the most likely reason for cancer recurrence and metastasis. Accumulating evidences have showed that traditional Chinese medicine (TCM) has significant effect on CSCs. It could inhibit the proliferation, self-renew, and multidifferentiation of CSCs. We aimed to summarize the theories of CSCs in TCM, the inhibitory effect, and the pathway on CSCs of TCM. This review will provide potential new strategies and alternative perspectives for CSCs treatments and basic research into complementary and alternative medicine.

1. Introduction

Local and distant recurrence of malignant tumors following radio- and/or chemotherapy correlates with poor prognosis of patients. Among the reasons for cancer recurrence, cancer stem cells (CSCs) are considered the most likely cause [1, 2]. Cancer stem cells (CSCs) are small subpopulations of neoplastic cells within a tumor, usually less than 5 percent, which are able to generate new tumors in appropriate animal hosts. These cells divide asymmetrically which on one hand yield CSCs and on the other hand differentiate into neoplastic cells forming tumor tissue [35]. It has been demonstrated that cancer stem cells derive from normal stem cells and differentiated somatic cells that undergo transformation and dedifferentiation, respectively, under certain conditions [1], which have self-renewal and differentiation abilities [6]. Additionally, the thought that CSCs are the cause of tumorigenesis, progression, invasion, metastasis, chemoradiotherapy resistance, and relapse makes their analysis more important [7, 8]. The American Association for Cancer Research (AACR) in 2006 sought to unify conceptions of this cell type. In their working definition, the AACR determined that a cancer stem cell is “a cell within a tumor that possesses the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor” [9, 10]. These cells had many similarities to stem cells, such as self-renewal, multidifferentiation [1113], similar growth mechanism [14], and activity of telomerase [15], and both transfer to different tissues [16]. Traditional Chinese medicines (TCM) have drawn a great deal of attention in recent years for their potential in the treatment of cancer. And accumulating evidences have showed that traditional Chinese medicine has significant effect on CSCs. So it is necessary to further research the effect of TCM on CSCs.

2. TCM and Cancer Stem Cells

The theory of cancer stem cell is proposed in past decade, so there is no record about CSCs in ancient Chinese medicine. According to CSC’s biological behaviors and effects on tumor metastasis or recurrence, 3 ideas had been put forward about CSCs in TCM.

2.1. Essence Deficiency Had a Close Relationship with CSCs

Stem cells could differentiate into normal cells which are basic components in life. In ancient Chinese medicine, the records of CSCs were included in the theories of Essence, Five Elements, and Visceral Manifestation [1719]. Qi is the basic component in body, which participates and maintains activities in life. Essence deriving from the kidney could promote growth of body as the power of life. Essence, which is the origin of all things in the universe, is the power of the qi in life and is indispensable in life activities. It is similar to stem cells, so we classify stem cells as Essence of kidney in TCM [20]. Under the physiological condition, Essence of kidney plays an important role in life activities. When Essence of kidney is insufficient, the tumor occurs and metastasizes. CSCs which have the abilities of self-renewal, differentiation, and oncogenicity are derived from mutant stem cells and related to tumor occurrence and metastases. Accordingly, Essence of kidney deficiency had a close relationship with CSC.

2.2. Imbalance of Ying and Yang Could Induce CSCs

Researches have shown that the cause of oncogenesis may relate to CSCs regulate by the niche where they reside. Now few treatments have targeted cancer stem cells. The factors in the niche, controlling CSCs, are similar to the characteristics of yin-yang in traditional Chinese medicine. Under physiological conditions, regulated factors in the niche controlling oncogenes and suppressor genes, proliferation, differentiation and apoptosis, and activation and inactivation of signal transduction pathways are maintained in a balanced condition in order to regulate the normal quantity of stem cells. It is similar to the function of yin and yang in TCM theory; for example, the oncogenes resemble yang, and suppressor genes resemble yin. Once the balance of oncogenes (yang) and suppressor genes (yin) is destroyed, the proliferation of CSC would be out of control, cancer would occur, and relapse and metastasis would develop. Therefore, it is important to suppress oncogenes (yang) or activate suppressor genes (yin) to control the proliferation of CSC [21]. So, the treatment on the regulation of the niche of CSC is quite necessary according the principle of yin-yang in TCM [21].

2.3. Phlegm Might Be One of the Causes to Induce CSCs

Usually, the lump is pigeonholed as phlegm in TCM. Zhu Danxi thought that most of lumps in body were induced by “phlegm,” and the phlegm belonged to tangible phlegm. Though CSCs were fewer in total tumor cells, they were the most important factors to induce tumor occurrence and metastasis. So, from this point, CSC was similar to tangible phlegm. Intangible phlegm, which was another type of phlegm, could arrive to all organs with qi moving. Zhu Danxi thought intangible phlegm was harmful to health, because of moving everywhere, from head to toe. And CSCs have lower ability of adhesion and cell polarity and higher ability of movement than tumor cells. So intangible phlegm had more close relationship with CSC [22, 23].

3. Effects and Mechanisms of TCM on CSCs

Accumulating evidences had revealed the existence of CSCs in the majority of leukemia cases and a number of solid tumors, including colorectal cancer [2427].The stem cell-like characteristics gave CSCs the capacities for continuous self-renewal, multidifferentiation, and natural drug resistance, resulting in cancer relapse and metastasis and leading to the eventual failure of clinical anticancer treatment [28, 29]. Therefore, discovering novel agents that target CSCs has the potential to improve the effectiveness of anticancer treatment.

Traditional Chinese medicines have gained great attention as certain naturally occurring compounds have been demonstrated to possess anti-CSC abilities [30, 31]. The research in animals has proved that curcumin and quinacrine liposomes not only could enhance apoptosis effects and endocytic effects of C6 glioma stem cells in vitro, but also could increase the survival period of brain glioma-bearing mice and inhibit the growth of gliomas in vivo [32]. The preclinical researches about influence of TCM on CSCs have found that traditional Chinese medicine could affect CSCs on stages in the growth of CSCs; for example, resveratrol can inhibit the cancer cells form spheres at the formation of CSCs [33] and sulforaphane has an inhibitory effect on biological behaviors, which are the important features of CSCs, such as self-renewal, proliferation, and differentiation [3436], and some traditional Chinese medicines not only inhibit the behaviors of CSCs, but also could reverse drug resistance and promote autophagy. Therefore, it is necessary to research the effects and mechanisms of TCM on CSCs to help us find the new target of cancer therapy in clinic in future.

3.1. TCM Has Effect on CSCs by Inhibiting CSCs Viability

Hedyotis diffusa Willd was a drug to treat cancer in TCM, with the heat-clearing, detoxicating, and antitumor effect. The ethanol extract of Hedyotis diffusa Willd [30] could inhibit colon cancer stem cells sphere formation, differentiation in vitro by downregulating the β-catenin and TCF4 mRNA, and inhibiting β-catenin/Wnt pathway and CK20 and CD133 mRNA in colon cancer stem cells, which was time-dose dependent. In addition, the researches had showed that bufalin which was the main component of Chansu could inhibit tumor cells proliferation [31] and promote apoptosis [3739]. Yeh et al. [40] found that bufalin inhibited the stemness of osteosarcoma cancer stem cells. Moreover, the research showed that miR-148a might be a target of bufalin, and miR-148a downregulated DNMT1 and p27 to inhibit the stemness of OS cells. Honokiol (HNK) could inhibit sphere formation and stemness in melanoma cells. It significantly decreased the number and size of microspheres in a dose dependent manner. And western blot showed that HNK significantly enhanced phosphorylation of AMPK in melanoma cells [41].

3.2. TCM Has Effect on CSCs by Inducing CSCs Apoptosis

CD133 was a marker in lung cancer stem cells. CD133 cells in A549 were fewer after treatment by nanorealgar. Nanorealgar could induce both A549 cells and A549 cancer stem cells apoptosis and reduce the number of cancer stem cells in a dose dependent manner by caspase dependent mitochondrial pathway, but the sensitivity of cancer stem cells to nanorealgar was much lower than the A549 cells [34]. Sulforaphane induced prostatic cancer stem cells apoptosis by inducing caspase-3 and dephosphorylation FKHR, and it also could upregulate caspase-3, PARP, and BAX and downregulate Bcl-2 to induce chronic leukemia stem cells apoptosis [42].

TCM formulas had the same effect on CSCs. Sijunzitang serum could upregulate Bax and downregulate Bcl-2 to induce side population cells apoptosis and suppress proliferation in gastric cancer [43]. And TCM formulas combined with chemotherapy induced lung cancer stem cells apoptosis, because of the herbs in formulas which had qi-benefiting and Essence-nourishing effect and suppressed Wnt pathway [44].

3.3. TCM Could Arrest CSCs Cell Cycle at G0/G1

Evodiamine was a component of a traditional Chinese medicine, which selectively targets CSCs of breast cancer at a concentration that does show a little or no cytotoxic effect on bulk cancer cells. Evodiamine could make bulk cancer cells accumulate at the G2/M phase [45], while it selectively killed CSCs instead, not arresting CSCs in a specific cell cycle phase. In a high concentration, evodiamine kills CSCs and bulk cancer cells in the same mechanism, and in a low concentration, evodiamine could selectively activate p53 and p21 and decrease inactive Rb, the master molecules in G1/S checkpoint, which is more efficient in CSCs than bulk cancer cells. These data collectively suggested a novel mechanism involving CSCs-specific targeting by evodiamine and its possible use in the therapy of breast cancer [46]. Kan et al. formulas arrested nasopharyngeal carcinoma stem cells at G0/G1 and downregulated the CSCs marker CD44 and ABCG2 and induced CSCs apoptosis to kill cancer stem cells [47].

3.4. TCM Could Downregulate CSCs Markers

Cancer stem cell markers usually were divided into two parts: (1) the markers only expressed in cancer stem cells, such as CD133; (2) the markers expressed in both cancer stem cells and embryonic stem cell, such as Sox-2, Oct-4, and Nanog. These markers not only identified CSCs, but also affected the formation of CSCs.

Curcumin, a component of Jianghuang, could significantly inhibit sphere formation and dephosphorylation STAT3 [48], and water-soluble curcumin downregulated CD44+ and CD24+ by injection [49]. Sulforaphane (SNF) could inhibit SHh pathway, which targeted downregulating downstream Nanog, Oct4, VEGF, and PDGFR and inhibited pancreatic cancer stem cells ability of self-renewal [50]. Resveratrol not only induced apoptosis to inhibit CSCs self-renewal, but also could downregulate Sox-2, Oct-4, Nanog, c-Myc, and ABCG2. So, resveratrol could significantly inhibit CSCs metastasis and EMT [51].

3.5. TCM Could Sensitize CSCs to Chemotherapeutic Drugs by Reversing Drug Resistance

Mitomycin (MMC) or curcumin alone marginally reduced the BCSC population in mammospheres; however, together, they reduced the BCSC population in CD44+CD24−/low cells by more than 75%. Curcumin [52] sensitized breast cancer cells to chemotherapeutic drugs by reducing the BCSCs population mainly through a reduction in the expression of ABCG2 and ABCC1. It had demonstrated that fumitremorgin C, a selective ABCG2 inhibitor, reduced BCSCs survival to a similar degree as curcumin did. In addition, curcumin improved the sensitivity of paclitaxel, cisplatin, and doxorubicin in breast cancer cell lines MCF-7 and MDA-MB231, as shown by more than 2-fold decrease in the half-maximal inhibitory concentration of these chemotherapeutic agents.

Pien Tze Huang (PZH), a well-known TCM formula that was first prescribed more than 450 years ago in the Ming Dynasty, had been used in China and Southeast Asia for centuries as a folk remedy for various types of cancer [5355]. In addition, PZH could inhibit CSCs. And PZH significantly reduced the percentage and the viability and sphere-forming capacity of the colorectal cancer stem-like SP cells in a dose dependent manner, which indicated that PZH had ability of suppressing the growth of colorectal cancer stem cells. Moreover, PZH markedly downregulated the mRNA levels of ABCG1 and ABCG2, which were members of the ABC transporter superfamily and contributed to the SP phenotype and multidrug resistance. The dates suggested that inhibiting the growth of CSCs is a potential mechanism by which PZH could be used in cancer treatment [56].

3.6. TCM Could Promote CSCs Autophagy

Autophagy was normally a degradative mechanism for the removal of tumor of bulk cytoplasmic constituents through the endosomal/lysosomal system [30, 57, 58]. Previous studies revealed that autophagy was involved in the cell death induced by anticancer drugs such as 5-fluorouracil and rapamycin [59, 60]. And ginsenoside F2 (F2), a component of Renshen, was assessed for its antiproliferative activity against breast cancer stem cells (CSCs). F2 could induce the formation of acidic vesicular organelles, recruitment of GFP-LC3-II to autophagosomes, and elevation of Atg-7 levels, suggesting that F2 initiates an autophagic progression in breast CSCs [61].

3.7. TCM Could Inhibit CSCs Invasion

Brain tumor stem cells had played an important role in tumor occurrence and invasion. It had a close relationship with tumor invasion and prognosis [62]. The traditional Chinese medicine for promoting blood circulation and removing blood stasis could upregulate TIMP1 mRNA to enhance the inhibitory effect of matrix metalloproteinase (MMPs) to inhibit invasion of BTSCs in vitro. The extracellular matrix (ECM) plays the role of a barrier in glioma cell invasion, and MMPs could degrade ECM and remove obstacle of glioma cells, leading to tumor invasion and metastasis. The dates showed that overexpression of TIMP could make MMP inactive by combining with it to inhibit tumor invasion [63].

The effects and mechanisms of traditional Chinese medicine or extracts of TCM on CSCs were listed in Table 1.

Effects on CSCsMechanisms

Sulforaphane [64]Inhibiting CSC self-renew
Wusan granules [65], centralizer class of anticancer traditional Chinese medicine [35]Inhibiting CSCs proliferation
Xiantansanjie [66]Inhibiting CSCs proliferationInhibiting Notch-1 pathway
Bufalin [40]Inhibiting CSCs proliferation, differentiation, and sphere formationmiR-148a downregulated DNMT1 and p27
Sanguinarine [67]Inhibiting CSC proliferation, invasion, and apoptosisInhibiting Wnt/β-catenin pathway
Ethanol extract of HDW [30, 66], sulforaphane [68]Inhibiting sphere formationInhibiting Wnt/β-catenin pathway
Resveratrol [69], brucine [70]Inhibiting sphere formation
Honokiol [41]Inhibiting sphere formationInducing AMPK phosphorylation
Curcumin [48], ursolic acid [33]Inhibiting sphere formationInhibiting STAT3 phosphorylation
Ursolic acid [71]Inhibiting proliferation and inducing apoptosisInhibiting EMT
Extract from Sophora flavescens [72], Feiyanning [44]Inhibiting CSCs proliferation and inducing apoptosisInhibiting Wnt pathway
Pien Tze Huang [73]Inhibiting the viability and promoting the apoptosis and differentiationsuppressing the Notch-1 pathway
Ginsenoside Rg3 [36], ginsenoside F2 [61], Huangqintang [74], Ligustrazine, tanshinone IIA [75]Inducing CSC apoptosis
Nanorealgar [34]Inducing CSC apoptosisActivating caspase-3
Fuzheng Jiedu, verticine, peiminine [76]Inducing CSC apoptosisInhibiting EMT, downregulating TGF-β/Smad pathway
Sulforaphane [42]Inducing CSC apoptosisActivating caspase-3, inhibiting FKHR phosphorylation
Sijunzitang [43]Inducing CSC apoptosisUpregulating the expression of apoptosis protein BAX and downregulating Bcl-2
Rottlerin [77]Inducing CSC apoptosisInhibiting PI3K/Akt/mTOR pathway and activating caspase in cascade
Evodiamine [46]Arresting CSC cell cycleActivating p53-p21-Rb pathway
Yiqijiedu [47]Arresting CSC cell cycle, inhibiting the expression of CSC marker, and inducing apoptosis
Jieduxiaozhengyin, Fuzhengyiliu [78], ginsenoside Rg3 [79], tetrandrine [80], curcumin [49]Inhibiting the expression of CSC marker
Resveratrol [52]Inhibiting the expression of Nanog and Oct4
Sulforaphane[50]Inhibiting the expression of Nanog and Oct4Inhibiting Shh pathway
Honokiol [67]Inhibiting the expression of CD133Inhibiting Notch-1 pathway
The traditional Chinese medicine for promoting blood circulation and removing blood stasis [63]Inhibiting CSCs invasionInducing TIMP1 mRNA and inhibiting MMP
Ligustrazine [81, 82]Inhibiting CSCs invasionInhibiting the expression of the integrin, CD44V6, VEGF, and HIF-1α
Isoliquiritigenin [70], Ligustrazine, tanshinone IIA [83]Reversing drug resistanceInhibiting β-catenin/ABCG2 pathway
Curcumin [52, 84], Jianpiyiwei [85], Pien Tze Huang [56]Inhibiting the expression of ABCG2

4. The Pathway about CSCs in TCM

Cancer stem cells derived from mutant stem cells, so the pathway which affected stem cells also could affect CSCs [35, 64, 65], such as Wnt, Hedgehog, and Notch; meanwhile some new pathways were found in further research on CSCs. Now we only introduce the pathways about CSC treated by TCM.

4.1. Notch-1 Pathway

Ponnurangam [67] had showed that the combination of honokiol and IR reduced numbers and size of spheroids, which was coupled with reduced expression of CSC marker protein DCLK1. In addition, there were reduced levels of activated Notch-1, its ligand Jagged-1, and the downstream target gene Hes-1. Furthermore, expression of components of Notch-1 activating γ-secretase complex (presenilin 1, nicastrin, Pen2, and APH-1) was also suppressed. On the other hand, the honokiol effects were mitigated when the Notch intracellular domain was expressed. In addition, the honokiol-IR combination reduced levels of DCLK1 and the Notch signaling-related proteins in the xenograft tissues. Together, these data suggested that honokiol was a potent inhibitor of colon cancer growth that targets the stem cells by inhibiting the γ-secretase complex and the Notch signaling pathway. Zhang [66] had found that Xiaotansanjie could inhibit CSCs proliferation, the expression of VEGF, angiogenesis, and microvessel density (MVD) in a dose dependent manner in vitro. And further research showed that Xiaotansanjie decoction inhibits CSC proliferation and angiogenesis was related to the downregulation of Notch-1 and Hes1.

4.2. Wnt/β-Catenin Pathway

Honokiol exerted many anticancer effects on various types of cancer cells [68]. The research explored its effects on the elimination of cancer stem-like side population (SP) cells. Honokiol did dependently reduce the proportion and induced apoptosis of SP. And it inhibited the CD44 and Wnt/β-catenin pathway of SP cells. The Wnt signaling transducers, such as β-catenin and TCF-4, were decreased in honokiol-treated SP cells, while the β-catenin degradation promoting kinase GSK-3 α/β was increased. Consistently, the protein levels of β-catenin downstream targets such as c-Myc and cyclin D1 were also downregulated. Furthermore, the β-catenin-related EMT markers such as Slug and Snail were markedly suppressed by honokiol. The findings indicated honokiol might be able to eliminate cancer stem cells through apoptosis induction, suppression of Wnt/β-catenin pathway, and inhibition of EMT [69]. Wnt/β-catenin could also affect cancer stem cells differentiation and viability in colon cancer stem cells. Hedyotis diffusa Willd inhibited β-catenin and TCF4 gene transcription in Wnt/β-catenin pathway, suppressed the activity of Wnt/β-catenin, which inhibited the transcription of gene CK20 and gene CD133, and affected CSC differentiation and viability [30]. Sulforaphane could inhibit breast cancer stem cell growth to 80% and the microsphere formation to 75% at the concentration of 5 mol/L. It was demonstrated that sulforaphane downregulated Wnt/β-catenin to inhibit ALDH+ cells proliferation in vivo [70].

4.3. Hedgehog Pathway

The Hedgehog (Hh) signaling pathway controls tissue polarity, patterning maintenance, and stem cell maintenance during embryonic development [86].The recent researches find that Hh pathway has close relationship with CSCs self-renewal. Lu et al. [87] found that Scutellaria barbata could suppress the cell viability and ability of self-renewal and downregulate the colon cancer stem cells markers CD133 and Lgr5 mRNA in dose dependent manner. The inhibitory effect at 500 μg/ml of Scutellaria barbata is the same as GANT61 which is the inhibitor of Hedgehog pathway at 10 μg/m. Further research shows that Scutellaria barbata could significantly suppress Ptch1 mRNA and Gli1 mRNA in Hedgehog pathway. When Hedgehog (mainly SHh) binds with the Ptch receptor (mainly Ptch1), the Hedgehog signaling pathway is activated. At this time, Smo inhibitor which is released by active Pth releases signaling cascade to make Gli (especially Gli1) be activated and transfer into the nucleus to make target gene transfer, such as Ptch, Gli, and Hip (Hip1) which inhibit Hedgehog disperse. That leads to CSC self-renewal [88].

4.4. Rb-p21-p53 Pathway

Evodiamine significantly increased the proportion of CSCs at the G1 stage and caused a massive volume of dying cells in a dose dependent manner, while the bulk cells were arrested at G2/M but not serious cell death yet. The mechanism showed that the decrease of expression was seen in phosphor-Rb (Ser795 and Ser 807/811), the master gene at the G1/S transition. Additionally, cyclin B1 and Fox M1, a key cyclin and key transcription factor at the G2/M stages, respectively, significantly diminished. The DNA breakage surveillance protein Chk1 and the TYRO3 which was required for G1/S transition in breast cancer cell decreased as well. p21, another key cell cycle blocker at G1/S, was found to increase the most by evodiamine. And the RPPA results showed that p53 and the phosphorylation of Akt were increased by evodiamine in CSLC, not in bulk cancer cells. Overall, p53 and p21 activation followed by Rb activation were the events that led to CSC death at the G1/S checkpoint [46].

4.5. β-Catenin/ABCG2 Pathway

Accumulating evidence has shown that β-catenin signaling in CSCs has a close relationship with chemoresistance and ABCG2 expression. Isoliquiritigenin (ISL), a compound of Gancao, had synergistic effects with chemotherapeutic drugs to inhibit breast cancer cell proliferation and colony formation. ISL could limit the SP and CSCs ratios by inhibiting self-renewal and multidifferentiation abilities in breast cancer. The research showed that ISL could activate the proteasome degradation pathway to inhibit β-catenin/ABCG2 signaling. GRP78 is the direct target of ISL. ISL inhibited ATPase activity by docking into the ATP domain of GRP78, which resulted in its dissociation from β-catenin. ISL could also enhance the sensibility of chemotherapy breast CSCs via the GRP78/β-catenin/ABCG2 pathway, with little toxicity in normal tissues and mammary stem cells. Therefore, the research has suggested that ISL could enhance breast CSCs chemosensitivity and highlight the significance of GRP78 in mediating cancer drug resistance and β-catenin signaling in CSCs [70].

4.6. PI3K/Akt/mTOR Pathway

The research about pancreatic cancer stem cells found that [79] rottlerin could reduce the viability of pancreatic cancer stem cells and induce apoptosis to form cytoplasm cavity and upregulate autophagy markers LC3-I, LC3-II, Atg7, and Beclin-1. Further research showed that phosphorylation of Akt and mTOR was inhibited to induce apoptosis, downregulate Bcl-2 and Bcl-X1, upregulate Bax, and activate caspase-3 and caspase-9 in CSCs treated by rottlerin. In addition, Akt inhibitor promoted CSC apoptosis induced by rottlerin. Silencing genes Atg7 and Beclin-1 or autophagosome inhibitor significantly inhibited apoptosis and autophagy induced by rottlerin. Therefore, rottlerin might induce CSC autophagy to apoptosis by inhibiting PI3K/Akt/mTOR pathway.

4.7. TGF-β/Smad Pathway

TGF-β could induce epithelial mesenchymal transition (EMT) and CSCs formation in breast cancer by releasing cross membrane signaling to induce Smad2/Smad3 to combine with Smad4 to activate Smad pathway, which could upregulate N-cad, VIM, and FN. Fuzheng Jiedu decoction significantly inhibited the expression of protein of EMT, such as E-cadherin, N-cadherin, and vimentin. Further research showed that Fuzheng Jiedu decoction might inhibit TGF-βmRNA and phosphorylation of Smad2/3 to inhibit TGF-β/Smad pathway and EMT to inhibit CSC formation [78].

4.8. AMPK Pathway

Honokiol (HNK) is a compound derived from Hopu, a plant that has been used in traditional Chinese medicine. Many researches showed HNK has antitumor activity with relatively low toxicity. HNK [42] could significantly inhibit the spheroid forming and stemness in melanoma cells. HNK significantly and dose-dependently reduced the number and size of melanospheres and the cellular ATP pool. The research suggested the AMPK pathway plays a central role in cellular energy homeostasis and acts as an energy sensor in cells. And further research showed that honokiol enhanced phosphorylation of AMPK to induce AMPK activation in melanoma cells.

Except for the signaling pathways mentioned above, there are others to affect the cancer stem cells; for example, FOXO3/LKB1/AMPK/PGC-1β/PDHA1 pathway is essential for CD44 expression and CSCs properties [89]; the mutual regulation between STAT3 and miR-181b could induce esophageal cancer stem-like cells proliferation and apoptosis resistance via CYLD pathway [90], and miR-34c-5p inhibits amphiregulin (AREG) to suppress ovarian cancer stemness and drug resistance via the AREG-EGFR-ERK pathway [91]. But whether TCM could via these pathways have effect on CSCs is not clear. In general, the factors which have a close relationship with CSCs are mainly epithelial mesenchymal transition (EMT) and Niche [92, 93]. So study of the pathways in EMT and Niche and influence of TCM on them may be the new way to CSCs therapy.

5. Conclusions

The mechanisms about cancer stem cells were complicated and varied. It was difficult to inhibit cancer stem cells only by targeting single pathway or mechanism. Traditional Chinese medicine was a huge goldmine and played an important role in the treatment of cancer stem cells. It had more advantages than western medicine, such as multiple targets in CSC treatment. So TCM combined with chemotherapy or radiotherapy had significant effects on CSC. The preclinical and clinical researches had demonstrated that TCM significantly inhibits tumor recurrence, metastasis, and prolonged survival [33, 71]. It was important to further study how TCM worked in CSC treatment and the effect of combining with chemotherapy or radiotherapy to improve the 5-year survival and the quality of life of cancer patients. However, the researches on CSC still had some problems: (1) The compounds of Chinese medicine were complex, especially, and had different biological function. Serum pharmacology was a common method of in vitro studies on TCM compound formulas [72], but the chemicals in TCM in serum are unstable and interfere with other factors. Therefore, serum pharmacology was not entirely accepted in TCM basic science. So new method about pharmacology is necessary. (2) TCM had a recorded history of over 2,000 years that may be used to guide modern treatments for disease and identify neglected but potentially useful treatment strategies [73]. However this process is based on ancient TCM theories of tradition and history that fail to take into account evidence-based medicine. An increasing number of clinical trials investigating a variety of TCM interventions have been registered in international trial registries, and the design of registered TCM trials has improved by using techniques such as sample size estimation, blinding, and placebos [36]. While the researches about CSC in TCM were few in clinic, so the high-level clinical evidence for CSC in TCM may be our target in future.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.


This work was supported by National Natural Science Foundation of China (no. 81173450).


  1. T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 1, pp. 105–111, 2001. View at: Google Scholar
  2. C. T. Jordan, M. L. Guzman, and M. Noble, “Cancer stem cells,” The New England Journal of Medicine, vol. 355, no. 12, pp. 1253–1261, 2006. View at: Publisher Site | Google Scholar
  3. D. Dick, “Human acut emyeloid leukemia is organize dasahierarchy that originates from aprimitive hematopoietic cell,” Nature Med, vol. 3, pp. 730–737, 1997. View at: Google Scholar
  4. T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859, pp. 105–111, 2001. View at: Publisher Site | Google Scholar
  5. S. Takaishi, T. Okumura, S. Tu et al., “Identificationofgastriccancerstemcells using thecellsurfacemarkerCD44,” Stem cells, vol. 27, no. 5, pp. 1006–1020, 2009. View at: Google Scholar
  6. K. Polyak and W. C. Hahn, “Roots and stems: Stem cells in cancer,” Nature Medicine, vol. 12, no. 3, pp. 296–300, 2006. View at: Publisher Site | Google Scholar
  7. C. J. Eaves, “Cancer stem cells: Here, there, everywhere?” Nature, vol. 456, no. 7222, pp. 581-582, 2008. View at: Publisher Site | Google Scholar
  8. T. N. Almanaa, M. E. Geusz, and R. J. Jamasbi, “A New Method for Identifying Stem-Like Cells in Esophageal Cancer Cell Lines,” Journal of Cancer, vol. 4, no. 7, pp. 536–548, 2013. View at: Publisher Site | Google Scholar
  9. M. F. Clarke, J. E. Dick, P. B. Dirks et al., “Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells,” Cancer Research, vol. 66, no. 19, pp. 9339–9344, 2006. View at: Publisher Site | Google Scholar
  10. S. D. Girouard and G. Murphy, “Melanoma stem cells: not rare, but well done,” Lab Invest, vol. 91, no. 5, pp. 647–664, 2011. View at: Google Scholar
  11. “The cancer stem cell hypothesis: failures and pitfalls,” Neurosurgery, vol. 68, no. 2, pp. 531–545, 2011. View at: Google Scholar
  12. B. B. Tysnes and R. Bjerkvig, “Cancer initiation and progression: involvement of stem cells and the microenvironment, BBARev,” Cancer, vol. 1775, no. 2, pp. 283–297, 2007. View at: Google Scholar
  13. W. Guo, J. L. Lasky, and H. Wu, “Cancer stem cells,” Pediatric Research, vol. 59, no. 4 Pt 2, pp. 59R–64R, 2006. View at: Google Scholar
  14. C. T. Jordan, “Cancer stem cell biology: From leukemia to solid tumors,” Current Opinion in Cell Biology, vol. 16, no. 6, pp. 708–712, 2004. View at: Publisher Site | Google Scholar
  15. S. Pathak, “Organ-and tissue-specific stem cells and careinogenesis,” Anti-cancer Res, vol. 22, no. 3, pp. 1353–1356, 2002. View at: Google Scholar
  16. J. Zheng, “Cellular and molecular biology cancer,” Shanghai: Shanghai Science and Technology Press, pp. 150–167, 2011. View at: Google Scholar
  17. J. Zhang, Z. W. Xu, S. H. Du et al., “Stem cells and the theory of “Essence”,” Study Journal of Traditional Chinese Medicine, vol. 22, no. 7, pp. 1198–1200, 2004. View at: Google Scholar
  18. P. Y. Liu and G. X. Cai, “The relationship between Essence and stem cell in biology,” Journal of Hunan College of Traditional Chinese Medicine, vol. 23, no. 6, pp. 29-30, 2003. View at: Google Scholar
  19. D. S. Xiao, L. D. Yu, G. Y. Yu et al., “The relationship five elements and stem cells,” Zhejiang Journal of Tradition Chiese medicine, vol. 42, no. 11, pp. 669–671, 2007. View at: Google Scholar
  20. Z. W. Xu, J. Zhang, and M. Zhang, “Stem cell transplantation to treat ischemic heart failure based on heart and kidney related,” Journal of Yunnan University of Traditional Chinese Medicine, no. 5, p. 14, 2009. View at: Google Scholar
  21. W.-R. Xu, H.-S. Lin, X.-Y. Chen, and Y. Zhang, “Yin-yang balance therapy on regulating cancer stem cells,” Journal of Traditional Chinese Medicine, vol. 31, no. 2, pp. 158–160, 2011. View at: Publisher Site | Google Scholar
  22. M. Ye and J. Shi, “The relationship between phlegm and tumor stem cells in traditional Chinese Medicine,” China Medical Herald, vol. 13, no. 28, pp. 80–94, 2016. View at: Google Scholar
  23. B. Yan, Z. F. Qin, and P. K. Wei, “The theory of phlegm and gastric cancer stem cells,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 19, no. 7, pp. 93–95, 2012. View at: Google Scholar
  24. T. Lapidot, C. Sirard, J. Vormoor et al., “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” Nature, vol. 367, no. 6464, pp. 645–648, 1994. View at: Publisher Site | Google Scholar
  25. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, “Prospective identification of tumorigenic breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3983–3988, 2003. View at: Publisher Site | Google Scholar
  26. C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,” Nature, vol. 445, no. 7123, pp. 106–110, 2007. View at: Publisher Site | Google Scholar
  27. L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi et al., “Identification and expansion of human colon-cancer-initiating cells,” Nature, vol. 445, no. 7123, pp. 111–115, 2007. View at: Publisher Site | Google Scholar
  28. M. Dean, T. Fojo, and S. Bates, “Tumour stem cells and drug resistance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 275–284, 2005. View at: Publisher Site | Google Scholar
  29. B.-B. S. Zhou, H. Zhang, M. Damelin, K. G. Geles, J. C. Grindley, and P. B. Dirks, “Tumour-initiating cells: challenges and opportunities for anticancer drug discovery,” Nature Reviews Drug Discovery, vol. 8, no. 10, pp. 806–823, 2009. View at: Publisher Site | Google Scholar
  30. L. Wei, P. Chen, Y. Chen, A. Shen et al., “Pien Tze Huang suppresses the stem-like side population in colorectal cancer cells,” Molecular Medicine Reports, vol. 9, pp. 261–266, 2014. View at: Google Scholar
  31. T. Efferth, “Stem cells, cancer stem-like cells, and natural products,” Planta Medica, vol. 78, no. 10, pp. 935–942, 2012. View at: Publisher Site | Google Scholar
  32. W. Yahua, Y. Xue, X. Haolun, Y. Helu, L. Xia, and T. Hui, “The functional curcumin liposomes induce apoptosis in C6 glioblastoma cells and C6 glioblastoma stem cells in vitro and in animals,” International Journal of Nanomedicine, vol. 12, pp. 1369–1384, 2017. View at: Google Scholar
  33. P. R. Pandey, H. Okuda, M. Watabe et al., “Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase,” Breast Cancer Research and Treatment, vol. 130, no. 2, pp. 387–398, 2011. View at: Publisher Site | Google Scholar
  34. Y. Chang, Y. Zhao, W. Gu et al., “Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through Mir-148a,” Cellular Physiology and Biochemistry, vol. 36, no. 3, pp. 1186–1196, 2015. View at: Publisher Site | Google Scholar
  35. R. K. Srivastava, S. N. Tang, W. Zhun et al., “Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells,” Front Biosci, vol. 1, no. 3, pp. 515–528, 2011. View at: Google Scholar
  36. Y. Zhang, “cal behavior of cancer stem cell like cells in human breast cancer MCF-7 cell line,” China Academy of Chinese medical Science, vol. 4, 2009. View at: Google Scholar
  37. Y. R. Shi, H. Xu, M. Y. Shi et al., “Hedyotisdiffusa willd inhibit colon cancer stem cells differentiation by Wnt pathway,” Pharmacology and Clinics of Chinese Materia Medica, vol. 31, no. 1, pp. 133–136, 2015. View at: Google Scholar
  38. K.-Q. Han, G. Huang, W. Gu, Y.-H. Su, X.-Q. Huang, and C.-Q. Ling, “Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice,” World Journal of Gastroenterology, vol. 13, no. 24, pp. 3374–3379, 2007. View at: Publisher Site | Google Scholar
  39. M. Watabe, K. Ito, Y. Masuda, S. Nakajo, and K. Nakaya, “Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells,” Oncogene, vol. 16, no. 6, pp. 779–787, 1998. View at: Publisher Site | Google Scholar
  40. J.-Y. Yeh, W. J. Huang, S.-F. Kan, and P. S. Wang, “Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells,” Prostate, vol. 54, no. 2, pp. 112–124, 2003. View at: Publisher Site | Google Scholar
  41. D. Li, X. Qu, K. Hou et al., “PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells,” Anti-Cancer Drugs, vol. 20, no. 1, pp. 59–64, 2009. View at: Publisher Site | Google Scholar
  42. G. Kaushik, D. Kwatra, D. Subramaniam, R. A. Jensen, S. Anant, and J. M. V. Mammen, “Honokiol affects melanoma cell growth by targeting the AMP-activated protein kinase signaling pathway,” American Journal of Surgery, vol. 208, no. 6, pp. 995–1002, 2014. View at: Publisher Site | Google Scholar
  43. Y. Yang, J. Chen, J. Yi et al., “Induction effect of realgar nanoparticles on lung cancer A549 cells and cancer stem cell apoptosis,” Pharmacology and Clinics of Chinese Materia Medica, vol. 26, no. 6, p. 39, 2010. View at: Google Scholar
  44. L.-C. Lin, C.-T. Yeh, C.-C. Kuo et al., “Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function,” Journal of Agricultural and Food Chemistry, vol. 60, no. 28, pp. 7031–7039, 2012. View at: Publisher Site | Google Scholar
  45. J. Li, “Effect of Sijunzitang on proliferation and apoptosis of gastric cancer side populationcells,” Beng Bu Medcine, vol. 5, 2013. View at: Google Scholar
  46. S. Wang, L. F. Wang, Z. Y. Xu et al., “The effect of Feiyanning on Wnt pathway in lung cancer stem cells,” Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai, vol. 26, no. 6, pp. 77–82, 2012. View at: Google Scholar
  47. S.-F. Kan, C.-H. Yu, H.-F. Pu, J.-M. Hsu, M.-J. Chen, and P. S. Wang, “Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3,” Journal of Cellular Biochemistry, vol. 101, no. 1, pp. 44–56, 2007. View at: Publisher Site | Google Scholar
  48. S. Han, J. K. Woo, Y. Jung et al., “Evodiamine selectively targets cancer stem-like cells through the p53-p21-Rb pathway,” Biochemical and Biophysical Research Communications, vol. 469, no. 4, pp. 1153–1158, 2016. View at: Publisher Site | Google Scholar
  49. Q. Y. Fan, “Effect of Yiqijiedu formula on cell cycle and cancer stem cell marker CD44 and ABCG2 expression in nasopharyngeal carcinomaCNE2,” Hu Nan University of Traditional Chinese Medicine, vol. 5, 2013. View at: Google Scholar
  50. L. Lin, Y. Liu, H. Li et al., “Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030,” British Journal of Cancer, vol. 105, no. 2, pp. 212–220, 2011. View at: Publisher Site | Google Scholar
  51. K. Wang, T. Zhang, L. Liu et al., “Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells,” International Journal of Nanomedicine, vol. 7, pp. 4487–4497, 2012. View at: Publisher Site | Google Scholar
  52. S.-H. Li, J. Fu, D. N. Watkins, R. K. Srivastava, and S. Shankar, “Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway,” Molecular and Cellular Biochemistry, vol. 373, no. 1-2, pp. 217–227, 2013. View at: Publisher Site | Google Scholar
  53. S. Shankar, D. Nall, S.-N. Tang et al., “Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition,” PLoS ONE, vol. 6, no. 1, Article ID e16530, 2011. View at: Publisher Site | Google Scholar
  54. Q. Zhou, M. Ye, Y. Lu et al., “Curcumin improves the tumoricidal effect of mitomycin C by suppressing ABCG2 expression in stem cell-like breast cancer cells,” PLoS ONE, vol. 10, no. 8, Article ID e0136694, 2015. View at: Publisher Site | Google Scholar
  55. A. Shen, J. Lin, and Y. Chen, “Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways,” Oncology Reports, vol. 30, no. 4, pp. 1701–1706, 2013. View at: Publisher Site | Google Scholar
  56. A. Shen, Y. Chen, F. Hong et al., “Pien Tze Huang suppresses IL-6-inducible STAT3 activation in human colon carcinoma cells through induction of SOCS3,” Oncology Reports, vol. 28, no. 6, pp. 2125–2130, 2012. View at: Publisher Site | Google Scholar
  57. Q. Zhuang, F. Hong, A. Shen et al., “Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model,” International Journal of Oncology, vol. 40, no. 5, pp. 1569–1574, 2012. View at: Publisher Site | Google Scholar
  58. B. Levine and D. J. Klionsky, “Development by self-digestion: Molecular mechanisms and biological functions of autophagy,” Developmental Cell, vol. 6, no. 4, pp. 463–477, 2004. View at: Publisher Site | Google Scholar
  59. B. Levine and G. Kroemer, “Autophagy in the pathogenesis of disease,” Cell, vol. 132, no. 1, pp. 27–42, 2008. View at: Publisher Site | Google Scholar
  60. N. Mizushima, B. Levine, A. M. Cuervo, and D. J. Klionsky, “Autophagy fights disease through cellular self-digestion,” Nature, vol. 451, no. 7182, pp. 1069–1075, 2008. View at: Publisher Site | Google Scholar
  61. X. H. Pan, X. L. Zhang, H. L. Sun, J. Zhang, M. Yan, and H. Zhang, “Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells,” PLoS ONE, vol. 8, no. 2, Article ID e56679, 2013. View at: Publisher Site | Google Scholar
  62. B. Ravikumar, C. Vacher, Z. Berger et al., “Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease,” Nature Genetics, vol. 36, no. 6, pp. 585–595, 2004. View at: Publisher Site | Google Scholar
  63. T. T. Mai, J. Moon, Y. Song et al., “Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells,” Cancer Letters, vol. 321, no. 2, pp. 144–153, 2012. View at: Publisher Site | Google Scholar
  64. J.-M. Liu, B.-Y. Mao, S. Hong, Y.-H. Liu, and X.-J. Wang, “The postoperative brain tumour stem cell (BTSC) niche and cancer recurrence,” Advances in Therapy, vol. 25, no. 5, pp. 389–398, 2008. View at: Publisher Site | Google Scholar
  65. J. M. Liu, L. W. Huang, P. Hu et al., “Effects of Chinese herbs for activating blood circulation and removing stasis on invasion ability and TIMP1 mRNA expression of C6 brain tumor stem cells,” Journal of New Chinese medicine, vol. 43, no. 8, pp. 192–194, 2013. View at: Google Scholar
  66. W. T. Zhang, “Study on the effect of five kinds of traditional Chinese medicine on the tumorigenicity of human breast cancer stem cell,” Guangxi Medicine University, 2012. View at: Google Scholar
  67. M. P. Shi, B. S. Zhong, L. Y. Gao et al., “Wu San Granule inhibit nucleic acidin malignant tumor cells in vitro,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 23, pp. 142-143, 2003. View at: Google Scholar
  68. J. Yang, Z. Fang, J. Wu et al., “Construction and application of a lung cancer stem cell model: antitumor drug screening and molecular mechanism of the inhibitory effects of sanguinarine,” Tumor Biology, vol. 37, no. 10, pp. 13871–13883, 2016. View at: Publisher Site | Google Scholar
  69. G. Sun, L. Wei, J. Feng, J. Lin, and J. Peng, “Inhibitory effects of hedyotis diffusa willd. On colorectal cancer stem cells,” Oncology Letters, vol. 11, no. 6, pp. 3875–3881, 2016. View at: Publisher Site | Google Scholar
  70. Y. Li, T. Zhang, H. Korkaya et al., “Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells,” Clinical Cancer Research, vol. 16, no. 9, pp. 2580–2590, 2010. View at: Publisher Site | Google Scholar
  71. X. Sun, “Study on MCF-7cell enrichment and identification and intervention of brucine on breast cancer stem cells,” Anhui Medical University, 2012. View at: Google Scholar
  72. W. Wenlong, Z. Chongqiang, and J. David, “Ursolic Acid Inhibits the Growth of Colon Cancer-initiating Cells by Targeting STAT3,” Anticancer Research, vol. 33, pp. 4279–4284, 2013. View at: Google Scholar
  73. J. Zhang, W. Wang, L. Qian, Q. Zhang, D. Lai, and C. Qi, “Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition,” Oncology Reports, vol. 34, no. 5, pp. 2375–2384, 2015. View at: Publisher Site | Google Scholar
  74. F. Qi, L. Wei, A. Shen et al., “Pien Tze Huang inhibits the proliferation, and induces the apoptosis and differentiation of colorectal cancer stem cells via suppression of the Notch1 pathway,” Oncology Reports, vol. 35, no. 1, pp. 511–517, 2016. View at: Publisher Site | Google Scholar
  75. Z.-G. Yang, H.-X. Sun, and Y.-P. Ye, “Ginsenoside Rd from Panax notoginseng is cytotoxic towards HeLa cancer cells and induces apoptosis,” Chemistry and Biodiversity, vol. 3, no. 2, pp. 187–197, 2006. View at: Publisher Site | Google Scholar
  76. S. Q. Zhang, “Effect of Scutellaria Decoction on proliferation of gastric cancer stem cells in vitro,” Fujian Universty of Traditional Medicine, 2014. View at: Google Scholar
  77. Y. Wang, P. Zhang, D. Yang et al., “Effect of Ligustrazine, TanshinoneIIA on aposis of PG stem like cells,” Liaoning Journal of Traditional Chinese Medicine, vol. 5, no. 45, pp. 1024–1028, 1120-1121, 2016. View at: Google Scholar
  78. Y. R. Zhang, “Research on the mechanism of prevention breast cancer metastasis by Fuzheng Qudu and its monomer composition of peimine inhibiting breast cancer stem cells epithelial mesenchymal transition,” Beijing University of Chinese Traditional Medicine, 2014. View at: Google Scholar
  79. B. N. Singh, D. Kumar, S. Shankar, and R. K. Srivastava, “Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells,” Biochemical Pharmacology, vol. 84, no. 9, pp. 1154–1163, 2012. View at: Publisher Site | Google Scholar
  80. Z. Y. Cao, X. Z. Chen, Y. Lin et al., “Effects of Chinese medicine on the expression of c-kit and CD133 in cancer stem cells of mice with hepatocellular carcinoma,” Journal of Fujian College of Traditional Chinese Medicine, vol. 2010, no. 3, pp. 18–20, 2010. View at: Google Scholar
  81. Y. Y. Luo, “Effects of Ginsenoside on invasion and the expression of CD133 in gastric cancer bearing nude mice,” Nanjing University of Traditional Chinese Medicine, 2014. View at: Google Scholar
  82. W. Xu, B. G. Debeb, L. Lacerda, J. Li, and W. A. Woodward, “Tetrandrine, a compound common in Chinese traditional medicine, preferentially kills breast cancer tumor initiating cells (TICs) in vitro,” Cancers, vol. 3, no. 2, pp. 2274–2285, 2011. View at: Publisher Site | Google Scholar
  83. D. Yang, P. Zhang, Y. Wang et al., “Effect of Ligustrazine on adhesion of PG-BE1 Stem Like Cells in the Pulmonary Giant Cell Carcinoma of Human with High Metastatic Lung Cancer,” Journal of Traditional Chinese Medicine, vol. 56, no. 13, pp. 1140–1144, 2015. View at: Google Scholar
  84. D. Yang, P. Zhang, Y. Wang et al., “Effect of TMP on the Expression of VEGF and HIF-1α of PG CSC Like Cells,” China Cancer, vol. 24, no. 3, pp. 234–240, 2015. View at: Google Scholar
  85. D. Yang, “Study about the effect of malignant biological characteristics of stem like cells by tetramethylprazine and tansfflnoneIIA, Beijing,” China Academy of Chinese Medical Science, 2015. View at: Google Scholar
  86. P. W. Ingham and A. P. McMahon, “Hedgehog signaling in animal development: paradigms and principles,” Genes & Development, vol. 15, pp. 3059–3087, 2001. View at: Google Scholar
  87. X. Lu, H. Xu, M. Shi et al., “Sculellaria barbata inhibit colon cancer stem cells self-renew by Hedgehog pathway,” Pharmacology and Clinics of Chinese Materia Medica, vol. 31, no. 1, pp. 139–141, 2015. View at: Google Scholar
  88. C. Karamboulas and L. Ailles, “Developmental signaling pathways in cancer stem cells of solid tumors,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1830, no. 2, pp. 2481–2495, 2013. View at: Publisher Site | Google Scholar
  89. M. Kumazoe, M. Takai, S. Hiroi et al., “FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma,” Journal of Biological Chemistry, vol. 292, no. 26, pp. 10813–10823, 2017. View at: Publisher Site | Google Scholar
  90. D.-D. Xu, P.-J. Zhou, Y. Wang et al., “Reciprocal activation between STAT3 and miR-181b regulates the proliferation of esophageal cancer stem-like cells via the CYLD pathway,” Molecular Cancer, vol. 15, no. 1, article no. 40, 2016. View at: Publisher Site | Google Scholar
  91. S. L. Tung, W. C. Huang, F. C. Hsu et al., “miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway,” Oncogenesis, vol. 6, article e326, no. 5, 2017. View at: Google Scholar
  92. E. Fessler, F. E. Dijkgraaf, F. De Sousa E Melo, and J. P. Medema, “Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame?” Cancer Letters, vol. 341, no. 1, pp. 97–104, 2013. View at: Publisher Site | Google Scholar
  93. M. C. Cabrera, R. E. Hollingsworth, E. M. Hurt et al., “Cancer stem cell plasticity and tumor hierarchy,” World Journal of Stem Cells, vol. 7, pp. 27–36, 2015. View at: Google Scholar

Copyright © 2017 Yaohan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.